<DOC>
	<DOCNO>NCT00286013</DOCNO>
	<brief_summary>The aim study evaluate feasibility define overall tolerance toxicity well relative dose-intensity cumulative dose deliver , association ofgemcitabine , oxaliplatin radiotherapy patient locally advance unresectable , non-metastatic pancreatic adenocarcinoma cholangiocarcinoma</brief_summary>
	<brief_title>Feasibility Radiotherapy Concomitant Gemcitabine Oxaliplatin Locally Advanced Pancreatic Cancer Distal Cholangiocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically proven unresectable adenocarcinoma pancreas cholangiocarcinoma evidence metastatic disease WHO performance status 0 1 Complete recovrey surgery case enteric and/or biliary tract bypass operation perform Maximum delay surgery : 8 week No previous coexistent malignant disease except non melanoma skin cancer adequately treat cervic carcinoma situ Adequate bon marrow reserve No previous chemotherapy radiotherapy Expected survival &gt; 6 month Active infection Metastatic disease Inadequate liver function derivative surgery Inadequate renal function Pregnancy , breast feeding Use investigational agent month enrollment Patients grade 2 neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>